DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tislelizumab
Tislelizumab
(PDCO) Minutes of the Meeting on 29 January - 01 February 2019
Natural Killer Cell-Based Immunotherapy for Acute Myeloid Leukemia
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
International Nonproprietary Names for Pharmaceutical Substances (INN)
Guillain-Barre Syndrome Caused by Tislelizumab and Axitinib
Stembook 2018.Pdf
Clinical Outcomes and Influencing Factors of PD‑1/PD‑L1 in Hepatocellular Carcinoma (Review)
2018 Medicines in Development for Cancer
(INN) for Biological and Biotechnological Substances
Immunotherapy Updates in Advanced Hepatocellular Carcinoma
DRUG NAME: Tislelizumab
Immune Checkpoint Inhibitors of PD-L1 As Cancer Therapeutics Akintunde Akinleye* and Zoaib Rasool
A61K9/51 (2006.01) — with International Search Report (Art
Lung Cancer 147 (2020) 259–268
The Efficacy and Safety of PD-1/PD-L1 Immune Checkpoint Inhibitors in Treating Advanced Urothelial Cancer: a Meta-Analysis of Clinical Trials
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
2020 Medicines in Development ꟷ Cancer
TAG Mail – 25 June 2020
Top View
Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
Tislelizumab Plus Chemotherapy As First-Line Treatment for Advanced Esophageal Squamous
Phase IA/IB Study of Single-Agent Tislelizumab, an Investigational Anti
Annexes to the 2019 Annual Report of the European Medicines Agency
Immunotherapy of Lymphomas
The Molecular Binding Mechanism of Tislelizumab, an Investigational Anti-PD-1 Antibody, Is Differentiated from Pembrolizumab and Nivolumab
Changes Highlighted Final Version Date of Issue
PDF of Antibody News
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Tislelizumab Plus Chemotherapy As First
Tislelizumab in Chinese Patients with Advanced Solid Tumors: an Open-Label, Non-Comparative, Phase 1/2 Study
Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: a Literature Review and Treatment Perspectives
Application for the Addition of Tislelizumab on the WHO Model List of Essential Medicines
Rxoutlook® 1St Quarter 2021
Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives
Global Offering
Annexes to the Annual Report of the European Medicines Agency 2020
Application for the Addition of Tislelizumab on the WHO Model List of Essential Medicines